Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

NCT04053673 is registered in ClinicalTrials.gov with Ribon Therapeutics, Inc. as lead sponsor.

NCT NCT04053673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04053673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
Lead sponsor
Ribon Therapeutics, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
August 1, 2019
Completion date
July 31, 2023
Enrollment
130 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult